<DOC>
	<DOC>NCT00316238</DOC>
	<brief_summary>To investigate dose-response of Rapid Acting Intramuscular Olanzapine in Agitated Patients with Schizophrenia</brief_summary>
	<brief_title>A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Patients must have schizophrenia that meets disease diagnostic criteria in DSMIVTR Patients must be inpatients during the study Patients must have a minimum total score of no less than 14 on the five items of the PANSSEC and at least one individual item score of no less than 4 using the 17 scoring system prior to the first injection of study drug Patients who have a known history of diabetes mellitus. Patients who have received treatment with antipsychotics or other prohibited concomitant medicines within 2 hours prior to the first IM study drug administration Patients who have had treatment with benzodiazepines within 4 hours prior to first IM study drug administration.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>